156 related articles for article (PubMed ID: 8975956)
1. Alteration of prostaglandin E2 and leukotriene B4 synthesis in chronic inflammatory bowel disease.
Schmidt C; Baumeister B; Kipnowski J; Schiermeyer-Dunkhase B; Vetter H
Hepatogastroenterology; 1996; 43(12):1508-12. PubMed ID: 8975956
[TBL] [Abstract][Full Text] [Related]
2. Arachidonic acid metabolism and intracellular calcium concentration in inflammatory bowel disease.
Schmidt C; Kosché E; Baumeister B; Vetter H
Eur J Gastroenterol Hepatol; 1995 Sep; 7(9):865-9. PubMed ID: 8574719
[TBL] [Abstract][Full Text] [Related]
3. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease.
Sharon P; Stenson WF
Gastroenterology; 1984 Mar; 86(3):453-60. PubMed ID: 6319219
[TBL] [Abstract][Full Text] [Related]
4. Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis.
Casellas F; Papo M; Guarner F; Antolín M; Segura RM; Armengol JR; Malagelada JR
Eur J Gastroenterol Hepatol; 1995 Mar; 7(3):221-6. PubMed ID: 7743303
[TBL] [Abstract][Full Text] [Related]
5. Prostanoid synthesis by cultured peripheral blood mononuclear cells in inflammatory diseases of the bowel.
Rachmilewitz D; Ligumsky M; Haimovitz A; Treves AJ
Gastroenterology; 1982 Apr; 82(4):673-9. PubMed ID: 6949849
[TBL] [Abstract][Full Text] [Related]
6. Blockade of leukotriene production by a single oral dose of MK-0591 in active ulcerative colitis.
Hillingsø J; Kjeldsen J; Laursen LS; Lauritsen K; von Spreckelsen S; Depré M; Friedman BS; Malmström K; Shingo S; Bukhave K
Clin Pharmacol Ther; 1995 Mar; 57(3):335-41. PubMed ID: 7697951
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical localization of vascular endothelial growth factor in colonic mucosa of patients with inflammatory bowel disease.
Griga T; May B; Pfisterer O; Müller KM; Brasch F
Hepatogastroenterology; 2002; 49(43):116-23. PubMed ID: 11941933
[TBL] [Abstract][Full Text] [Related]
8. Effect of aspirin on prostaglandin E2 and leukotriene B4 production in human colonic mucosa from cancer patients.
Frommel TO; Dyavanapalli M; Oldham T; Kazi N; Lietz H; Liao Y; Mobarhan S
Clin Cancer Res; 1997 Feb; 3(2):209-13. PubMed ID: 9815674
[TBL] [Abstract][Full Text] [Related]
9. Increased prostaglandin E2 and leukotriene B4 synthesis in isolated colonic mucosal cells in inflammatory bowel disease. a preliminary report.
Baumeister B; Schmidt C; Helisch A; Kipnowski J
J Clin Gastroenterol; 1996 Mar; 22(2):117-20. PubMed ID: 8742650
[TBL] [Abstract][Full Text] [Related]
10. Increased production of vascular endothelial growth factor by intestinal mucosa of patients with inflammatory bowel disease.
Griga T; Voigt E; Gretzer B; Brasch F; May B
Hepatogastroenterology; 1999; 46(26):920-3. PubMed ID: 10370639
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of VEGF and CD146 in patients with inflammatory bowel disease.
Tsiolakidou G; Koutroubakis IE; Tzardi M; Kouroumalis EA
Dig Liver Dis; 2008 Aug; 40(8):673-9. PubMed ID: 18374637
[TBL] [Abstract][Full Text] [Related]
12. [Local production of eicosanoids in patients with ulcerative colitis].
Lukás K; Lukás M; Jáchymová M
Cas Lek Cesk; 1995 Jan; 134(1):13-7. PubMed ID: 7712517
[TBL] [Abstract][Full Text] [Related]
13. Discriminant histological features in the diagnosis of chronic idiopathic inflammatory bowel disease: analysis of a large dataset by a novel data visualisation technique.
Cross SS; Harrison RF
J Clin Pathol; 2002 Jan; 55(1):51-7. PubMed ID: 11825925
[TBL] [Abstract][Full Text] [Related]
14. Different distribution of mast cells and macrophages in colonic mucosa of patients with collagenous colitis and inflammatory bowel disease.
Nishida Y; Murase K; Isomoto H; Furusu H; Mizuta Y; Riddell RH; Kohno S
Hepatogastroenterology; 2002; 49(45):678-82. PubMed ID: 12063968
[TBL] [Abstract][Full Text] [Related]
15. Mucosal and plasma prostaglandin E2 in ulcerative colitis.
Wiercinska-Drapalo A; Flisiak R; Prokopowicz D
Hepatogastroenterology; 1999; 46(28):2338-42. PubMed ID: 10521993
[TBL] [Abstract][Full Text] [Related]
16. Release of leukotriene B4 and 5-hydroxyeicosatetraenoic acid during phagocytosis of artificial immune complexes by peripheral neutrophils in chronic inflammatory bowel disease.
Nielsen OH; Elmgreen J; Thomsen BS; Ahnfelt-Rønne I; Wiik A
Clin Exp Immunol; 1986 Aug; 65(2):465-71. PubMed ID: 3024887
[TBL] [Abstract][Full Text] [Related]
17. Colorectal leukotriene B4 synthesis in vitro in inflammatory bowel disease: inhibition by the selective 5-lipoxygenase inhibitor BWA4C.
Hawthorne AB; Boughton-Smith NK; Whittle BJ; Hawkey CJ
Gut; 1992 Apr; 33(4):513-7. PubMed ID: 1316305
[TBL] [Abstract][Full Text] [Related]
18. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease.
Winterkamp S; Weidenhiller M; Otte P; Stolper J; Schwab D; Hahn EG; Raithel M
Am J Gastroenterol; 2002 Dec; 97(12):3071-7. PubMed ID: 12492192
[TBL] [Abstract][Full Text] [Related]
19. The effect of 5-aminosalicylate and para-aminosalicylate on the synthesis of prostaglandin E2 and leukotriene B4 in isolated colonic mucosal cells.
Schmidt C; Fels T; Baumeister B; Vetter H
Curr Med Res Opin; 1996; 13(7):417-25. PubMed ID: 8862941
[TBL] [Abstract][Full Text] [Related]
20. Drug treatment and formation of eicosanoids in patients with chronic inflammatory bowel disease.
Lauritsen K
Dan Med Bull; 1989 Sep; 36(4):378-93. PubMed ID: 2572403
[No Abstract] [Full Text] [Related]
[Next] [New Search]
